Inhaled Engineered Bacteria Clear Resistant Biofilms on Mechanical Ventilator Tubes

In a laboratory at the University of Barcelona, researchers have successfully deployed a genetically reprogrammed bacterium to clear drug-resistant infections from the breathing tubes of pigs. The inhaled treatment, delivered through a standard hospital nebulizer, marks a critical milestone in the development of "living medicines" for intensive care patients.[1][3]

The study, published today in the journal eBioMedicine, targets Pseudomonas aeruginosa, a stubborn pathogen that forms impenetrable slimy shields called biofilms on mechanical ventilators. These biofilms block conventional intravenous antibiotics, leaving intubated patients highly vulnerable to fatal respiratory complications.[1][2][5]

By repurposing a mild respiratory bacterium into a therapeutic delivery vehicle, the Spanish research team managed to thin these resilient biofilms by approximately 40 percent. The success in pigs—a large animal model with lung structures and immune responses closely mirroring those of humans—clears a major clinical hurdle.[1][3]

The silent pandemic in intensive care

Patients who cannot breathe independently rely on endotracheal tubes passed directly into their windpipes to sustain life. However, within days of placement, opportunistic bacteria colonize these sterile plastic surfaces, establishing protective biofilm communities that are notoriously difficult to eradicate.[3]

"Our work represents a different line of attack, and one we badly need," says Dr. Antoni Torres, a senior co-author from Hospital Clínic-IDIBAPS.[1]

Torres emphasized the severity of this daily clinical challenge, describing antibiotic resistance in these settings as a silent pandemic. He noted that it affects mechanically intubated patients constantly, necessitating entirely new therapeutic strategies.[3]

Pseudomonas aeruginosa is responsible for roughly one in four cases of ventilator-associated pneumonia, a condition that significantly increases mortality risk in intensive care units. The pathogen frequently demonstrates resistance to multiple classes of frontline antibiotics, severely limiting treatment options for critical patients.[3]

The bacteria's primary defense mechanism is its biofilm matrix, which acts as a physical fortress that standard drugs simply cannot penetrate. Because intravenous antibiotics struggle to reach the bacteria encased within this shield, patients frequently suffer from persistent, recurring infections.[3]

This persistent colonization not only drives up mortality rates but also extends the duration of mechanical ventilation and intensive care stays. Finding a way to breach the biofilm has become one of the most pressing priorities in modern infectious disease research.[3]

Engineering a microbial Trojan horse

To bypass the biofilm barrier, the research team turned to live biotherapeutics, an emerging field that uses living organisms as programmable medical treatments. They selected Mycoplasma pneumoniae, a bacterial species that typically causes mild respiratory infections, as their foundational biological chassis.[1][2]

Through targeted genetic modifications, the scientists stripped the bacterium of its pathogenic traits, rendering it entirely harmless to the mammalian host. They then loaded it with a customized genetic payload designed specifically to dismantle the defenses of P. aeruginosa.[1][3]

The engineered bacterium carries specific genes that produce enzymes capable of dissolving the structural sugars holding the biofilm matrix together. Simultaneously, it secretes targeted toxins that selectively destroy the Pseudomonas cells exposed by the dissolving shield.[1][3]

"Our study is part of an emerging field of medicine known as live biotherapeutics," explains Dr. Irene Rodríguez-Arce, a senior co-author from the Centre for Genomic Regulation.[1]

"In this case we've taken a bacterium naturally adapted to the lung and reprogrammed it so that it delivers therapeutic molecules instead of causing damage. It's a Trojan horse strategy against disease," Rodríguez-Arce adds.[1]

Unlike traditional drugs that wash through the bloodstream, the living medicine actively seeks out the target environment and produces its therapeutic payload on site. This localized production ensures high concentrations of the biofilm-busting enzymes exactly where they are needed most.[1][3]

Measurable success in a large animal model

The transition from small animal models to pigs represents a crucial validation step for experimental respiratory therapies. While the living medicine had previously shown efficacy in mice in 2023, the pig model provides a much more accurate simulation of human lung anatomy.[1][2]

Pigs share similar respiratory size, airway structure, and immune system characteristics with humans, making them the gold standard for testing pulmonary interventions. Success in this model strongly suggests that the biological mechanisms will translate effectively to human patients.[1][3]

The researchers administered the modified bacteria using a standard nebulizer, the exact same aerosol delivery device used in human intensive care units. This practical delivery method ensures that the therapy can be easily integrated into existing clinical protocols without requiring specialized equipment.[1][3]

Upon administration, the inhaled living medicine significantly degraded the bacterial shields lining the inner surfaces of the breathing tubes. Precise measurements showed the biofilm thickness reduced from 6.08 micrometers down to 3.67 micrometers, a reduction of roughly 40 percent.[1][3]

Subsequent microscopic examinations of the animal lung tissues confirmed the rigorous safety profile of the engineered strain. Researchers identified no signs of tissue damage or inflammatory cascades attributable to the modified Mycoplasma pneumoniae.[1][3]

Furthermore, the biological intervention exerted no measurable disruption on the pigs' native airway bacterial communities. This high degree of specificity confirms that the live biotherapeutic attacks only the target pathogen, leaving the host's natural commensal flora entirely undisturbed.[3]

Expanding the biotherapeutic arsenal

The preclinical data gathered from these large animal experiments provide the essential foundation required to support a future first-in-human clinical safety evaluation. The multi-institutional research consortium is currently preparing the regulatory groundwork to advance the therapy into clinical trials.[3]

AI

"I am confident that with modifications to the bacterial chassis' payload, we could completely dissolve the biofilms on the surface of endotracheal tubes and clear P. aeruginosa infections entirely," explains ICREA Research Professor Luis Serrano, a senior co-author.[1]

The research team is also actively exploring combination therapies to maximize the treatment's clinical efficacy. By pairing the aerosolized living medicine with traditional intravenous antibiotics, clinicians could strike the exposed Pseudomonas bacteria with a devastating dual-pronged attack.[1][3]

The potential applications for this engineered bacterial platform extend far beyond ventilator-associated pneumonia. The Centre for Genomic Regulation is actively designing adapted versions of the living medicine to combat other severe, intractable respiratory conditions.[1][2]

Future targets include complex pulmonary diseases where targeted molecular delivery remains a significant pharmacological challenge. Researchers are currently developing specialized bacterial strains aimed at treating pulmonary fibrosis and delivering localized therapies directly to lung cancer tumors.[1][2]

As antibiotic resistance continues to outpace the development of conventional small-molecule drugs, living medicines offer a dynamic and highly adaptable alternative. By rewriting the genetic code of microbes, scientists are transforming former pathogens into precise, programmable therapeutics.[1][3]

The success of this engineered Mycoplasma pneumoniae demonstrates that synthetic biology can provide practical solutions for the most stubborn hospital-acquired infections. The next critical checkpoint will be proving that this microbial Trojan horse performs just as safely in human intensive care units.[1][3]